potential indications for glp-1 receptor agonists keep expanding Can one drug do it all? Reviewing the clinical universe of 💊New GLP-1 pill gets FDA

In a single internally consistent radioligand series measuring inhibition of I-NDP-alpha-MSH binding to membranes from BHK570 cells stably expressing each human receptor, bremelanotide returned Ki values of 0.25 nM at MC4R, 6.4 nM at MC1R, 17 nM at MC5R and 53 nM at MC3R, corresponding to pKi 9.6, 8.2, 7.8 and 7.3 respectively

For skin rejuvenation, NAD+ IV therapy produces a faster and larger increase in cellular NAD+ than oral supplementation, making it the preferred delivery method in clinical protocols

Lipotropic injections are safe to use in the long-term but use is recommended for a minimum of 12 to 24 weeks

However, there were no significant differences in HbA1c reductions between any of the cotadutide dose groups and the liraglutide (1.8 mg) group